These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. [Predictive indicators for progression to severe complications(hemolytic-uremic syndrome and encephalopathy) and their prevention in enterohemorrhagic Escherichia coli infection]. Joh K Nihon Rinsho; 1997 Mar; 55(3):700-5. PubMed ID: 9086784 [TBL] [Abstract][Full Text] [Related]
29. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Johnson KE; Thorpe CM; Sears CL Clin Infect Dis; 2006 Dec; 43(12):1587-95. PubMed ID: 17109294 [TBL] [Abstract][Full Text] [Related]
30. [Study on diarrhea disease caused by enterohemorrhagic Escherichia coli O157:H7 in Xuzhou city, Jiangsu province in 2000]. Li H; Jing H; Pang B; Zhao G; Yang J; Xu J Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Apr; 23(2):119-22. PubMed ID: 12015094 [TBL] [Abstract][Full Text] [Related]
31. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome. Karch H; Friedrich AW; Gerber A; Zimmerhackl LB; Schmidt MA; Bielaszewska M Semin Thromb Hemost; 2006 Mar; 32(2):105-12. PubMed ID: 16575685 [TBL] [Abstract][Full Text] [Related]
32. [Novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin]. Nishikawa K Tanpakushitsu Kakusan Koso; 2008 Jan; 53(1):44-51. PubMed ID: 18186302 [No Abstract] [Full Text] [Related]
33. Nontoxigenic sorbitol-fermenting Escherichia coli O157:H- associated with a family outbreak of diarrhoea. Allerberger F; Dierich MP; Gruber-Moesenbacher U; Liesegang A; Prager R; Hartmann G; Rabsch W; Tschäpe H; Karch H Wien Klin Wochenschr; 2000 Oct; 112(19):846-50. PubMed ID: 11098536 [TBL] [Abstract][Full Text] [Related]
34. [Construction and immunization of a enterohemorrhagic Escherichia coli O157 attenuated]. Liu J; Sun Y; Feng SZ Sheng Wu Gong Cheng Xue Bao; 2007 Mar; 23(2):211-7. PubMed ID: 17460890 [TBL] [Abstract][Full Text] [Related]
35. [Genes involved in the virulence of enterohemorrhagic Escherichia coli]. Izumiya H; Watanabe H Nihon Rinsho; 1997 Mar; 55(3):641-5. PubMed ID: 9086773 [TBL] [Abstract][Full Text] [Related]
36. [Enterohemorrhagic Escherichia coli and hemolytic-uremic syndrome]. Allerberger F; Sölder B; Caprioli A; Karch H Wien Klin Wochenschr; 1997 Sep; 109(17):669-77. PubMed ID: 9381722 [TBL] [Abstract][Full Text] [Related]
37. [Characteristics and molecular biology of verotoxin produced by enterohemorrhagic Escherichia coli]. Iijima Y; Honda T Nihon Rinsho; 1997 Mar; 55(3):646-50. PubMed ID: 9086774 [TBL] [Abstract][Full Text] [Related]
38. Conserved Stx2 phages from Escherichia coli O103:H25 isolated from patients suffering from hemolytic uremic syndrome. Sekse C; Muniesa M; Wasteson Y Foodborne Pathog Dis; 2008 Dec; 5(6):801-10. PubMed ID: 19014273 [TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection. Gao X; Cai K; Shi J; Liu H; Hou X; Tu W; Xiao L; Wang Q; Wang H Vaccine; 2009 Mar; 27(14):2070-6. PubMed ID: 19428832 [TBL] [Abstract][Full Text] [Related]